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Background: Peptic ulcer diseases are common and are induced by many fac-
tors, including stress, smoking, and ingestion of non-steroidal anti-inflammatory 
drugs. Quercetin is considered to be an anti-oxidant with healing effects on many 
experimental toxic injuries. The present study aimed to explore the possible effect 
of quercetin on acute gastric ulcer induced by indomethacin in rats.
Materials and methods: Three groups received indomethacin (30 mg/kg body 
weight) orally by orogastric gavage on two consecutive days. The rats received 
famotidine (50 mg/kg body weight), quercetin (50 mg/kg body weight), or vehi-
cle alone for 15 consecutive days by oral gavage. The control group received no 
indomethacin but received vehicle for 15 days by oral gavage. The ulcer index, 
volume, and pH of gastric juice were measured, and the stomachs were examined 
by routine light microscopy. 
Results: Compared with the control group, the indomethacin-treated rats showed 
a marked damage of the gastric mucosal surface and a high ulcer index. In the 
famotidine- and quercetin-treated groups, significantly increased antioxidant 
enzyme activities were observed. The congestion, erosions, and necrosis were 
reduced with mild inflammatory cell infiltration while no major damage of en-
dothelial cells was observed in the treated rats. 
Conclusions: The findings of the study show that quercetin had antioxidant effect 
and can protect gastric mucosa against indomethacin-induced gastric ulceration 
than famotidine. (Folia Morphol 2017; 76, 2: 252–261)
Key words: flavonoids, ulceration, nonsteroidal anti-inflammatory drugs, 
pH value, gastric juice
INTRODUCTION
An inflammation, irritation or erosion of the mu-
cosal surface of the stomach is termed as gastritis, 
and it can range from a mild, asymptomatic form to 
severe ulceration [67]. When a gastric ulcer occurs 
in the lining of the stomach, it is known as a peptic 
ulcer, which refers to an open sore in the lining of 
the stomach or the duodenum [51]. Peptic ulcers are 
associated with high morbidity and morbidity and 
mortality related to many complications including 
bleeding, perforation, penetration and gastric outlet 
obstruction [6, 42, 51]. Moreover, many otherwise 
beneficial therapies, including low-dose aspirins, dual 
anti-platelet therapy and nonsteroidal anti-inflamma-
tory drugs (NSAIDs) such as indomethacin, have been 
shown to be important risk factors for recurrent ulcers 
and related complications [61]. It has been reported 
that about 25% of gastric ulcers are caused by NSAIDs 
[11]. NSAIDs are widely used for pain control and 
prevention of malignancies, strokes, pre-eclampsia, 
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Alzheimer’s disease, etc. [60, 73]. Furthermore, stud-
ies have reported that various non-pharmaceutical 
factors including stress, hunger and Helicobacter 
pylori invasion also cause gastric ulcers [63]. Hence, 
the prevention of gastrointestinal disorders, includ-
ing gastric ulcers, is of utmost importance for both 
medical professionals and researchers.
Many synthetic anti-ulcer drugs (e.g., misoprostol) 
have been developed that can be specifically used for 
preventing or treating NSAID-induced gastric ulcers 
[44]. However, these drugs have many side-effects 
such as diarrhoea, itching, skin rash, and dizziness 
[20]. Therefore, there is a renewed interest in non-
toxic, natural anti-ulcer formulations from medicinal 
plants [52]. Flavonoids are a naturally-occurring group 
of compounds with anti-inflammatory, anti-allergic, 
anti-viral, anti-bacterial and anti-tumour activities [14, 
72]. One of these flavonoids, quercetin (3, 5, 7, 3’, 
4’-pentahydroxyflavone), has been reported to have 
the ability to prevent oxidant injury and cell death 
by scavenging free oxygen radicals [43]. Quercetin 
is widely distributed in fruits and vegetables such as 
onions, apples, berries, and tea [48]. Studies have 
shown that daily intake of quercetin may decrease the 
risks of cardiovascular diseases [39], tumour develop-
ment, strokes and neurodegenerative diseases [53] 
by protection against oxidative DNA damage [21], 
lipid peroxidation [38] and inhibition of the release 
of inflammatory mediators [41]. Presently, quercetin 
is marketed in the United States primarily as a dietary 
supplement [69], with a recommended daily dose of 
200–1200 mg (probably due to variable absorption 
from the digestive tract) [19].
Experimental studies have shown that quercetin 
can prevent ethanol-induced gastric ulcers [31]. 
Therefore, the present study was undertaken to 
extend this finding by examining the effects of 
quercetin on indomethacin-induced gastric lesions 
in rats.
MATERIALS AND METHODS
Animal grouping 
Forty adult male albino rats (150–250 g body 
weight) were obtained from the animal house, Faculty 
of Medicine, Umm Al-Qura University. All animal pro-
cedures were performed according to the approved 
protocols and in accordance with the recommenda-
tions for the proper care and use of laboratory ani-
mals. The animals were categorised into four groups 
(10 in each):
 — Group 1 (control) received 1 mL of 1% sodium 
carboxymethyl cellulose (CMC) by oral gavage for 
15 consecutive days;
 — Group 2 received indomethacin (30 mg/kg body 
weight) dissolved in 1% CMC for 2 days, followed 
by 1% CMC for 15 consecutive days;
 — Group 3 received indomethacin in 1% CMC as 
in Group 2 and additionally received famotidine 
(50 mg/kg) dissolved in 1% CMC for 15 consecu-
tive days;
 — Group 4 received indomethacin in 1% CMC as in 
Group 2 and additionally received a suspension 
of quercetin (50 mg/kg body weight) in 1% CMC 
for 15 consecutive days.
Chemicals
Indomethacin (Sigma, Aldrich) was dissolved in 
1% sodium CMC to prepare a solution. After the ani-
mals had been fasted for 24 h but with free access to 
tap water, they were administered 1 mL of this solu-
tion orally (30 mg/kg body weight) for 2 consecutive 
days to induce acute gastric ulcer [3].
Famotidine tablets (Famotidine was purchased 
from Medical Union Pharmaceutical [MUP] Company, 
Abou Sultan — Ismailia, Egypt.) were crushed and 
dissolved in a small volume of CMC. Then 1 mL of this 
solution was administered to the animals by orogas-
tric gavage (Famotidine was 50 mg/kg administered 
as suspension 1% sodium CMC [2 mL, oral] once daily 
for 15 consecutive days.), starting from 6 h after the 
final indomethacin administration [36, 58].
Quercetin (Sigma, Aldrich, Germany) was sus-
pended in 1% sodium CMC immediately before 
its administration by orogastric gavage. A dose of 
50 mg/kg body weight was administered to the ani-
mals daily for 15 consecutive days, starting from 6 h 
after indomethacin administration [45].
Measurement of gastric juice volume and acidity
On the last day of the experimental period, all 
the rats were fasted for 12–14 h and were allowed 
to have access to only drinking water. The abdomen 
was incised after scarification by ether anaesthesia, 
and both the stomach and duodenum were exposed. 
A fistula made by a poly-ethane tube was inserted into 
the stomach via a small incision made in the duodenum 
and held in place by a ligature around the pylorus. The 
oesophagus was also clamped to prevent reflux and 
loss of gastric mucosa. The collected fluid was placed in 
tubes and centrifuged for 5 min at 5000 rpm, and the 
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volume of the supernatant was expressed as mL/100 g 
body weight. The acid output was determined by 
titrating with 0.01 NNaOH using phenolphthalein as 
an indicator and was expressed as μEq/6 h as output. 
The volume of gastric juice was measured by a gradu-
ated cylinder and expressed in mL [55]. 
Macroscopic and ulcer index study
The stomach of the rats was opened longitudi-
nally, spread out, pinned, and washed with saline. 
The lesions in the mucosa were examined under 
a 10× magnifying glass to assess the ulcer formation, 
and the number and severity of the ulcers per stom-
ach (see below). Digital images were taken for the 
whole stomach of each animal to serve as a perma-
nent record. Lesions of the mucosa ranging from 
hyperaemia at one extreme, through haemorrhagic 
lesions, and up to full erosions at the other extreme 
were recorded. The ulcer index of each animal was 
calculated by using the following scoring system [45]: 
 — 0 = normal coloured stomach;
 — 0.5 = red coloration;
 — 1 = spot ulceration;
 — 1.5 = haemorrhagic streaks;
 — 2 = ulcers between 3 and 5 mm in greatest di-
mension;
 — 3 = ulcers greater than 5 mm in greatest dimension;
 — 4 = perforations.
The mean ulcer score for each animal was ex-
pressed as the ulcer index. The effectiveness of the 
two treatments (famotidine and quercetin) was then 
calculated as a curative ratio using the following 
equation: Curative ratio (CR) = (LC − LT / LC) × 100, 
where LC is the ulcer index in rats treated solely with 
indomethacin and LT is the ulcer index in rats treated 
with indomethacin along with a therapeutic treat-
ment (either famotidine or quercetin) [55].
Measurement of gastric enzyme activity
The activities of the enzymes, i.e., gastric-reduced 
glutathione (GSH), superoxide dismutase (SOD) and 
catalase (CAT), in rat stomach tissues were deter-
mined. For each biochemical estimation, 0.5 g of the 
whole gastric tissue sample was taken and ground 
with liquid nitrogen in a mortar. The ground tissues 
were then treated with 4.5 mL of the appropriate 
buffer (such as Tris-HCl buffer or phosphate buffer). 
The mixtures were homogenised on ice using an 
Ultra-Turrax homogeniser for 15 min. The homogen-
ates were then used for determining the enzymatic 
activities. All assays were carried out at the room 
temperature in triplicates [25].
Determination of GSH. The mucosal surface of 
the stomach was collected by scraping, and then 
weighed and homogenised in 2 mL of 50 mM Tris-HCl 
buffer containing 20 mM EDTA and 0.2 mM sucrose 
(pH 7.5). Then the homogenate was immediately pre-
cipitated with 0.1 mL of ice-cold 25% trichloroacetic 
acid, centrifuged at 4000 rpm for 40 min at 4°C. The 
supernatant was used for the determination of GSH 
levels. Absorption was measured at 412 nm using 
a spectrophotometer. The GSH levels in the gastric 
mucosa were expressed as nmol/mg tissue [18]. 
Assay of SOD. The SOD was estimated based 
on the generation of superoxide radicals produced 
by xanthine and xanthine oxidase, which react with 
nitro blue tetrazolium to form Formosan dye. The SOD 
activity was then measured at 560 nm by the degree 
of inhibition of this reaction and was expressed as 
mmol/min/mg tissue [12].
Assay of CAT. The decomposition of H2O2 
was carried out in the presence of CAT at 240 nm. The 
CAT activity was defined as the amount of enzyme 
required to decompose 1 nmol of H2O2 per minute, 
at 25°C and pH 7.8. The stomach tissues were ho-
mogenised in a potassium phosphate buffer solu- 
tion (0.05 M; pH 7.4) and then centrifuged at 
3215 rpm for 15 min. A hydrogen peroxide solution 
(0.05 M) was prepared with potassium phosphate buffer, 
and the substrate solution for the assay. A volume 
of 0.1 mL of the supernatant was mixed with 1.9 mL 
of phosphate buffer solution, and the absorbance 
decline was measured at 240 nm. The results were 
expressed as mmol/min/mg tissue [50].
Histological study
The specimens from the stomachs of all rats were 
fixed in 10% formalin and were then processed to 
form paraffin blocks. Serial sections of 5 μm in thick-
ness were prepared and subjected to routine haema-
toxylin and eosin (H&E) staining [7].
Statistical analysis
All the results were expressed as mean ± standard 
error of the mean (SEM). The t-test for comparison 
between groups and one-way analysis of variance 
(ANOVA) for multi-sample groups at p < 0.05 were 
used to assess statistical significance in various groups 
of animals by using SPSS program version 2.01 (SPSS, 
2008, UK).
255
A.G.R. Alkushi, N.A.M. Elsawy, Effect of quercetin’s anti-ulcer activity
Biological activities
Antioxidant. A diet rich in flavonoids reduces the 
risk for oxidative-stress related chronic diseases such 
as asthma [35], diabetes [2], coronary heart disease 
[28], lung cancer [71], and stroke [49]. Antioxidation 
could be a result of metal chelation [4], scavenging of 
radicals [68], enzyme inhibition [56], and/or induction 
of the expression of protective enzymes [46].
Within the flavonoid family, quercetin is the most 
potent scavenger for reactive oxygen species (ROS), 
including O2 [15], and reactive nitrogen species (RNS) 
like nitric oxide [8], and ONOO [29]. Quercetin has 
been shown to be an excellent in vitro antioxidant 
activity [62]. 
Anti-inflammatory. Cyclooxygenase and lipoxy-
genase play an important role as inflammatory media-
tors. They are involved in the release of arachidonic 
acid, which is a starting point for a general inflamma-
tory response. Quercetin is known to possess strong 
anti-inflammatory capacities [27].
Quercetin’s anti-inflammatory activity appears 
to be due to its antioxidant and inhibitory effects on 
inflammation-producing enzymes (cyclooxygenase, 
and lipoxygenase) and the subsequent inhibition of 
inflammatory mediators, including leukotrienes and 
prostaglandins [9].
Antiulcer effects. Quercetin has been shown to 
have antiulcer and gastroprotective effects [16]. An 
interesting aspect of quercetin’s anti-ulcer effect is 
that it has been shown to inhibit growth of H. pylori 
in a dose-dependent manner in vitro [59].
It was reported that quercetin inhibits oxidative 
damage in ethanol-induced gastric lesions of rats [31].
It was found that the oral use of quercetin before 
and after administration of diclofenac sodium has 
been shown to be associated with fewer ulcers in 
test animals [74].
With oral administration to mice and rats, querce-
tin consistently did not induce any significant changes 
in several mutagenicity/genotoxicity endpoints (i.e., 
micronuclei, chromosomal aberrations, sister chro-
matid exchange, unscheduled DNA synthesis, and 
alkali-labile DNA damage) in somatic cells in com-
parison to untreated controls. Quercetin has been 
studied for its potential carcinogenicity in numerous 
long-term experimental animal studies, the major-
ity of which indicated no evidence of significantly 
increased incidences of neoplasm formation related 
to its oral administration. Human studies have failed 
to show any adverse effects associated with the oral 
administration of quercetin in a single dose of up 
to 4 g or after 1 month of 500 mg twice daily [54]. 
Organs weight analysis hearts, lungs, livers, spleens, 
and kidneys of the sacrificed rats were carefully removed, 
washed with saline solution, dried with filter paper, and 
weighed independently. The relative organs weight was 
calculated as previously described (Chapman et al., 
1959) using the following equation: Relative organ’s 
weight: Organ weight = Total body weight/100 [10].
RESULTS
Macroscopic examination (Fig. 1; Table 1)
The gross examination of the stomach lining 
of the control rats showed that the mucosa had 
a whitish colour with prominent rugae. However, the 
examination of the mucosal lining in indomethacin-
treated rats revealed haemorrhages or linear breaks/
erosions to the mucosal surface. In addition, the 
ulcer index in the rats of this treated group was very 
high, with an average of 40.52 ± 0.73 mm. This con-
firms the effectiveness of the treatment in inducing 
peptic ulcers. However, indomethacin-treated rats 
who had additionally received either famotidine or 
quercetin showed fewer hyperaemic areas and linear 
brown lesions. The ulcer index for the rats treated 
with famotidine was 27.3 ± 0.66 mm, which is sig-
nificantly lower than that of the group treated with 
indomethacin alone (p < 0.05). The rats treated with 
quercetin showed an ulcer index of only 19.55 ± 
± 0.62 mm, which was significantly lower than all the 
other indomethacin-treated groups (p < 0.05). Thus, 
it is clear that the treatment of animals with quercetin 
produced more effective protection against gastric 
ulcers compared to the treatment with famotidine.
Biochemical studies
Gastric juice volume. The volume of gastric juice 
obtained from rats with indomethacin-induced gas-
tric ulcer (control + ve) untreated ulcer group was 
substantially greater than that in normal control rats 
(0.8 ± 0.14 mL compared with 0.26 ± 0.05 mL) (Table 2). 
Comparatively, indomethacin-treated rats that also re-
ceived either quercetin or famotidine did not exhibit any 
increase in the volume of gastric juice (0.22 ± 0.15 and 
0.30 ± 0.42, respectively) compared to control animals.
Gastric juice pH. The pH of gastric juice was found 
to be reduced in indomethacin-treated rats (mean 
3.07 ± 0.58) compared with that of the normal rats 
(4.57 ± 0.24) (Table 2). However, indomethacin-treated 
rats who also received quercetin had pH values similar to 
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that of the controls. The pH values of those rats who 
received famotidine were even less acidic (5.52 ± 0.21).
Levels of gastric enzyme activity. The antioxi-
dant markers GSH, SOD and CAT were found to be 
significantly decreased in the indomethacin-treated 
group when compared with the control group. How-
ever, those indomethacin-treated rats that were sub-
sequently treated with either famotidine or quercetin 
had levels of antioxidant markers closer to that of the 
normal group and significantly higher than those of 
rats treated with indomethacin alone (Table 3).
Table 1. Effect of different treatments on indomethacin-induced 
ulcers
Group Ulcer index ± SEM [mm] Curative ratio [%]
Control 0 –
Indomethacin (I) 40.5 ± 0.7 –
I + famotidine 27.3 ± 0.7* 32.6
I + quercetin 19.5 ± 0.6** 51.7
All values are expressed as mean ± standard error of the mean (SEM), n = 10 animals 
in each group. There are significant differences between rats treated with famotidine or 
quercetin and those treated with indomethacin alone (p < 0.05).
*Significant difference between famotidine group (IIb) vs. indomethacin-treated group (IIa), 
p < 0.05. **Highly significant difference between quercetin-treated group (IIc) vs. 
indomethacin-treated group (IIa), p < 0.05
Figure 1. Gastric mucosa appearance in stomachs of control group (A), indomethacin-induced ulcer group (B), famotidine-treated group (C), 
and quercetin-treated group (D).
Table 2. Effect of different treatments on the volume and pH of 
the gastric juice (mean ±SEM, mL)
Group Gastric juice volume  
(mean ± SEM; mL)
Gastric juice pH 
(mean ± SEM)
Control 0.26 ± 0.1 4.6 ± 0.2
Indomethacin (I) 0.8 ± 0.1 3.1 ± 0.6
I + famotidine 0.22 ± 0.1** 5.5 ± 0.2*
I + quercetin 0.30 ± 0.4* 4.6 ± 0.01**
All values are expressed as mean ± standard error of the mean (SEM), n = 10 animals 
in each group. 
*Significant difference between famotidine group (IIb) vs. indomethacin-treated group (IIa), 
p < 0.05. **Highly significant difference between quercetin-treated group (IIc) vs. 
indomethacin-treated group (IIa), p < 0.05
Table 3. Effects of different treatments on the level of glutathione 
and various enzymes in different experimental groups
Group GSH [μmol/L] SOD [U/mL] CAT [μmol/L]
I 4.05 ± 0.06 44.06 ± 0. 6 229.30 ± 2.7
IIa 1.01 ± 0.02 21.80 ± 0.4 101.20 ± 2.2
IIb 2.32 ± 0.03 28.80 ± 0.60* 156.85 ± 3.6*
IIc 3.38 ± 0.04 37.2 ± 0.65** 199.58 ± 4.1**
GSH — glutathione; SOD — superoxide dismutase; CAT — catalase
All values are expressed as mean ± standard error of the mean, n = 10 animals in each 
group.  
*Significant difference between famotidine group (IIb) vs. indomethacin treated group (IIa),  
p < 0.05. **Highly significant difference between quercetin-treated group (IIc) vs. 
indomethacin-treated group (IIa), p < 0.05.
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mucosa. The gastric glands were found to be narrow, 
tightly packed, straight, and perpendicular to the 
surface epithelium, occupying the whole thickness 
of the lamina propria. The lamina propria contained 
blood vessels and smooth muscle fibres (Fig. 2). The 
glands contained mucous cells (columnar with pale 
cytoplasm), parietal cells (central rounded nuclei) and 
chief cells in the basal region (columnar with basal 
oval nuclei, basal basophilic cytoplasm, and pale api-
cal region) (Fig. 3). The resulting mucosal lesions in 
indomethacin-treated rats showed superficial dam-
age with a distorted shape of the gastric glands. The 
cells lining the damaged glandular area appeared to 
be shrunken with deeply acidophilic cytoplasm. The 
basal part of the gland showed loss of architecture 
and inflammatory cells in the lamina propria with 
dilated and congested capillaries (Fig. 4).
The H&E-stained sections in famotidine-treated 
rats showed deep eosinophilic cytoplasmic epithelial 
cells with vacuolisation of some cells and an increase 
in mucus-secreting cells with inflammatory cells in 
the lamina propria and widened gastric pits (Fig. 5).
Figure 6. A photomicrograph of a section of the fundus of a rat 
from the quercetin-treated group showing normal gastric mucosa 
with some inflammatory cells (I) and congested blood vessels (V) 
in the lamina propria (H&E staining,×100).
Figure 2. Fundus of a normal rat from the control group. The lamina 
propria contained blood vessels and smooth muscle fibres (H&E 
staining, ×100).
Figure 3. A section of the stomach fundus of a rat from control group 
showing surface columnar mucous cells (H&E staining, ×400).
Figure 4. A section of the fundus of an indomethacin-treated rat  
(H&E staining, ×400).
Figure 5. A section of the stomach of a rat from the famotidine-
-treated group (H&E staining, ×100).
Histological results
The H&E-stained sections of the stomachs of 
control rats showed normal histology of the gastric 
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In quercetin-treated rats, the gastric mucosa was 
found to be similar to the control group with some 
inflammatory cells and congested blood vessels in 
the lamina propria (Fig. 6).
DISCUSSION
Flavonoids are a group of naturally occurring com-
pounds that are widely distributed as secondary me-
tabolites in the plant kingdom. Quercetin, a flavonoid, 
prevents oxidant injury and cell death using several 
mechanisms, such as scavenging oxygen radicals [1]. 
The present study assessed the effects of quercetin on 
gastric ulceration induced by indomethacin in adult 
male albino rats. Like other NSAIDs, indomethacin is 
an analgesic that exhibits side effects such as ulcero-
genic action on stomach [40].
Quercetin’s anti-inflammatory activity appears 
to be due to its antioxidant and inhibitory effects on 
inflammation-producing enzymes (cyclooxygenase, 
lipoxygenase) and the subsequent inhibition of in-
flammatory mediators, including leukotrienes and 
prostaglandins [34]. Inhibition of histamine release by 
mast cells and basophiles also contribute to querce-
tin’s anti-inflammatory activity [33].
In the present study, we observed various macro-
scopic changes in the gastric mucosa. Normal white 
gastric mucosal rugae with a reduction in ulcer in-
dex were observed in both the control group and 
indomethacin-treated rats who also received querce-
tin. Contrarily, severe redness of the mucosa with 
brown haemorrhagic patches and a very high ulcer 
index were observed in those rats treated with indo-
methacin alone. These findings are similar to previous 
reports [65] in which the redness was attributed to 
vasodilatation and congestion of blood vessels, and 
the brown colorations were due to the effect of HCl 
on the haemorrhagic lesions.
The biochemical results showed that the volume 
of gastric secretion and its acidity were increased and 
the gastric enzymes were significantly decreased in 
indomethacin-treated rats compared with the con-
trol group. These results are in agreement with the 
findings of Seckin et al. [57]. Moreover, we also ob-
served the destruction of the mucosal epithelial cells 
as well as a highly eosinophilic cytoplasm and pyk-
notic nuclei along the length of fundic glands from 
the neck to the base. This is in agreement with the 
study of Drăghia [17], which reported a decrease in 
oxidative activity in the surface epithelium and vas-
cular endothelium. NSAIDs, such as indomethacin, 
produce beneficial effects through their ability to 
block cyclooxygenase, thereby inhibiting prostaglan-
din production [23]. Decreased prostaglandin level 
contributes to the pathogenesis of gastroduodenal 
mucosal ulcerations [26]. In addition, mucosal lesions 
due to NSAID-induced gastrointestinal damage are 
associated with an increase in ROS such as superox-
ide radical anions and hydroxyl radicals [64]. These 
mechanisms, including those related to prostaglandin 
suppression, lead to microvessel occlusion and subse-
quent hyper-production of reactive oxygen metabo-
lites. In particular, indomethacin causes gastric ero-
sions with increased lipid peroxidation and decreased 
glutathione peroxidase activity [47]. The presence 
of superoxide anions (O2−) may be responsible for 
the gastric damage as well as other tissue damage. 
Therefore, many researchers have focused on oxygen-
derived free radicals. This mechanism, in combination 
with ROS, damages membrane proteins by inducing 
lipid peroxidation and attacking unsaturated fatty ac-
ids [24]. Therefore, antioxidant defence systems and 
their components, including antioxidant enzymes, 
foods, and drugs, are considered to be important in 
preventing the toxic and disease-causing effects of 
oxygen-derived free radicals. Oxygen-handling cells 
have antioxidant enzymes that can protect them [66]. 
Both famotidine and quercetin treatments restored 
the gastric mucosa to near normality. However, the 
famotidine-treated rats had inflammatory cells infil-
tration with congested blood vessels in their lamina 
propria, whereas the quercetin-treated rats had an 
increase in surface mucous cells due to the increase in 
the apical cytoplasmic content of mucus granules. In 
addition, a widening of the gastric pits with increased 
mucus secretion was also observed. The histological 
results of the indomethacin group were confirmed by 
that of Fawcett’s [22] study, which reported an ap-
parent increase in mucin in stomachs in which most 
of the surface mucous cells were filled with rounded 
mucoid granules. The role of gastric mucins has been 
widely explained as forming a barrier between the 
surface epithelial cells and gastric juices; mucus may 
have the ability to resist enzymatic hydrolysis due to its 
carbohydrate moieties. Acidic mucin may have a role in 
protecting the pit cells against the effect of HCl during 
its passage. The alternating layers of neutral and acidic 
mucins in the surface coat act as a safeguard against 
HCl and other digestive enzymes in the lumen [70].
Studies have shown that some of the altered cells 
lack the ability to recover [5]. In this study group, 
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the treatment with indomethacin led to the loss 
of architecture and vacuolation of cells while the 
quercetin treatment resulted in a normal mucosa 
except for an increase in mucus granules in surface 
mucus cells. Quercetin exerts antioxidant influences 
by several mechanisms; these include scavenging 
oxygen radicals, protecting against lipid peroxidation, 
and chelating metal ions [37]. The high antioxidant 
activity of quercetin may be attributed to its capacity 
to diffuse through the cell membrane at a high rate 
[32]. Quercetin induces a decrease in the proinflam-
matory cytokines [30]. Gastric mucosa can be repaired 
after mucosal injury by mucosal restitution and re-
epithelisation by sloughing off the damaged cells. This 
is achieved by rapid migration of viable stem cells to 
the injured site to replace the dead cells during ulcer 
healing [13]. However, human studies have failed to 
show any adverse effects associated with the oral 
administration of quercetin in a single dose of up 
to 4 g or after 1 month of 500 mg twice daily [54].
One of the limitation of this study is that quercetin 
has been studied for its potential carcinogenicity in 
numerous long-term experimental animal studies, 
the majority of which indicated no evidence of sig-
nificantly increased incidences of neoplasm formation 
related to its oral administration.
CONCLUSIONS
Quercetin has effective anti-ulcer activity against 
indomethacin-induced ulcerogenesis, and it can be 
used for therapy of ulcerogenesis and gastric mucosal 
injury. In particular, patients treated with NSAIDs may 
benefit from the consumption of a quercetin-rich diet.
Acknowledgements
Mohamed Abdelwahab Abo rehab, Assistant prof. 
Pharmaceutics Departments, Faculty of Pharmacy, 
Umm Al-Qura University, Saudi Arabia — for his help 
in quercetin preparation.
Eman Mohammed Faruk, Department of Histology 
and Cell Biology, Benha Faculty of Medicine, Egypt — 
for her valuable comments on this article.
REfERENCES
1. Abrahamse S, Kloots W, Amelsvoort Jv. Absorption, dis-
tribution, and secretion of epicatechin and quercetin in 
the rat. Nutr Res. 2005; 25(3): 305–317, doi: 10.1016/j.
nutres.2004.10.013.
2. Aguirre L, Arias N, Macarulla MT, et al. Beneficial Effects 
of Quercetin on Obesity and Diabetes. The Open Nutra-
ceuticals J. 2011; 4: 189–198, doi:10.2174/1876396001
104010189.
3. Alqasoumi S, Al-Sohaibani M, Al-Howiriny T, et al. Rocket. 
World J Gastroenterol. 2009; 15(16): 1958–1965, indexed 
in Pubmed: 19399927.
4. Amić D, Davidović-Amić D, Beslo D, et al. SAR and QSAR 
of the antioxidant activity of flavonoids. Curr Med Chem. 
2007; 14(7): 827–845, indexed in Pubmed: 17346166.
5. Asar M, Kayişli UA, Izgüt-Uysal VN, et al. Cadmium-
induced changes in epithelial cells of the rat stomach. 
Biol Trace Elem Res. 2000; 77(1): 65–81, indexed in Pub-
med: 11097472.
6. Asefa Z, G/eyesus A. Perforated peptic ulcer disease in 
Zewditu Hospital. Ethiop Med J. 2012; 50(2): 145–151, 
indexed in Pubmed: 22924283.
7. Bancroft JD, Gamble M. Theory and practice of histological 
techniques. Churchill Livingstone, London 2007.
8. Boots AW, Haenen GR, Bast A. Health effects of quercetin: 
from antioxidant to nutraceutical. Eur J Pharmacol. 2008; 
585(2-3): 325–337, doi:10.1016/j.ejphar.2008.03.008, 
indexed in Pubmed: 18417116.
9. Brett A, Ghica ME. Electrochemical Oxidation of Quercetin. 
Electroanalysis. 2003; 15(22): 1745–1750, doi: 10.1002/
elan.200302800.
10. Chapman DG, Castillo R, Campbell JA. Evaluation of 
protein in foods: 1. A method for the determination of 
protein efficiency ratios. Can J Biochem Phys. 1959; 37(5): 
679–686, doi: 10.1139/o59-074.
11. Chason RD, Reisch JS, Rockey DC. More favorable out-
comes with peptic ulcer bleeding due to Helicobacter py-
lori. Am J Med. 2013; 126(9): 811–818.e1, doi: 10.1016/j.
amjmed.2013.02.025, indexed in Pubmed: 23830535.
12. Chatterjee A, Chatterjee S, Biswas A, et al. Gallic Acid Enriched 
Fraction of Phyllanthus emblica Potentiates Indomethacin-
Induced Gastric Ulcer Healing via e-NOS-Dependent Pathway. 
Evid Based Complement Alternat Med. 2012; 2012: 487380, 
doi: 10.1155/2012/487380, indexed in Pubmed: 22966242.
13. Coşkun O, Kanter M, Armutçu F, et al. Protective effects 
of quercetin, a flavonoid antioxidant in absolute ethanol-
induced acute gastric ulcer. Eur J Gen Med. 2004; 1: 37–42.
14. Cotelle N. Role of flavonoids in oxidative stress. Curr 
Top Med Chem. 2001; 1(6): 569–590, indexed in Pub-
med: 11895132.
15. Cushnie T, Lamb A. Antimicrobial activity of flavonoids. Int 
J Antimicrob Agents. 2005; 26(5): 343–356, doi: 10.1016/j.
ijantimicag.2005.09.002.
16. Sánchez de Medina F, Gálvez J, González M, et al. Effects 
of quercetin on epithelial chloride secretion. Life Sci. 1997; 
61(20): 2049–2055, indexed in Pubmed: 9366512.
17. Drăghia AC. Histochemical and histopathological study of 
the gastric mucosa in the portal hypertensive gastropathy. 
Rom J Morphol Embryol. 2006; 47(3): 259–262, indexed 
in Pubmed: 17308685.
18. Dursun H, Bilici M, Albayrak F, et al. Antiulcer activity of 
fluvoxamine in rats and its effect on oxidant and antioxi-
dant parameters in stomach tissue. BMC Gastroenterol. 
2009; 9: 36, doi:  10.1186/1471-230X-9-36, indexed in 
Pubmed: 19457229.
19. Erlund I. Review of the flavonoids quercetin, hesperetin, 
and naringenin. Dietary sources, bioactivities, bioavailabil-
ity, and epidemiology. Nutr Res. 2004; 24(10): 851–874, 
doi: 10.1016/j.nutres.2004.07.005.
20. Ertem D. Clinical practice: Helicobacter pylori infection 
in childhood. Eur J Pediatr. 2013; 172(11): 1427–1434, 
260
Folia Morphol., 2017, Vol. 76, No. 2
doi:  10.1007/s00431-012-1823-4, indexed in Pub-
med: 23015042.
21. Farombi EO. Genotoxicity of chloroquine in rat liver cells: 
protective role of free radical scavengers. Cell Biol Toxicol. 
2006; 22(3): 159–167, doi:10.1007/s10565-006-0173-2, 
indexed in Pubmed: 16532284.
22. Fawcett DW. The Cell. W.B. Saunders Co, Philadelphia 
1981.
23. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-
steroidal anti-inflammatory drug-gastropathy. Dig 
Liver Dis. 2001; 33 Suppl 2: S35–S43, indexed in Pub-
med: 11827361.
24. Fornai M, Natale G, Colucci R, et al. Mechanisms of pro-
tection by pantoprazole against NSAID-induced gastric 
mucosal damage. Naunyn Schmiedebergs Arch Pharmacol. 
2005; 372(1): 79–87, doi: 10.1007/s00210-005-1075-1, 
indexed in Pubmed: 16080005.
25. Freitas FF, Fernandes HB, Piauilino CA, et al. Gastro-
protective activity of Zanthoxylum rhoifolium Lam. 
in animal models. J Ethnopharmacol. 2011; 137(1): 
700–708, doi:  10.1016/j.jep.2011.06.026, indexed in 
Pubmed: 21723384.
26. Genta RM. Differential diagnosis of reactive gastropathy. 
Semin Diagn Pathol. 2005; 22(4): 273–283, indexed in 
Pubmed: 16939055.
27. Geraets L, Moonen HJJ, Brauers K, et al. Dietary flavones 
and flavonoles are inhibitors of poly(ADP-ribose)polymer-
ase-1 in pulmonary epithelial cells. J Nutr. 2007; 137(10): 
2190–2195, indexed in Pubmed: 17884996.
28. Gross M. Flavonoids and Cardiovascular Disease. Arch 
Physiol Biochem. 2004; 42(s1): 21–35, doi: 10.1080/138802 
00490893483.
29. Heijnen CG, Haenen GR, van Acker FA, et al. Flavonoids 
as peroxynitrite scavengers: the role of the hydroxyl 
groups. Toxicol In Vitro. 2001; 15(1): 3–6, indexed in 
Pubmed: 11259863.
30. Jackson JK, Higo T, Hunter WL, et al. The antioxidants 
curcumin and quercetin inhibit inflammatory processes 
associated with arthritis. Inflamm Res. 2006; 55(4): 
168–175, doi:  10.1007/s00011-006-0067-z, indexed in 
Pubmed: 16807698.
31. Kahraman A, Erkasap N, Köken T, et al. The antioxidative 
and antihistaminic properties of quercetin in ethanol-
induced gastric lesions. Toxicology. 2003; 183(1-3): 
133–142, indexed in Pubmed: 12504347.
32. Kanter M, Aktas C, Erboga M. Protective effects of 
quercetin against apoptosis and oxidative stress in strep-
tozotocin-induced diabetic rat testis. Food Chem Toxicol. 
2012; 50(3-4): 719–725, doi: 10.1016/j.fct.2011.11.051, 
indexed in Pubmed: 22166789.
33. Kelly GS. Quercetin. Monograph. Altern Med Rev. 2011; 
16(2): 172–194, indexed in Pubmed: 21649459.
34. Kim HP, Mani I, Iversen L, et al. Effects of naturally-occur-
ring flavonoids and biflavonoids on epidermal cyclooxyge-
nase and lipoxygenase from guinea-pigs. Prostaglandins 
Leukot Essent Fatty Acids. 1998; 58(1): 17–24, indexed in 
Pubmed: 9482162.
35. Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake 
and risk of chronic diseases. Am J Clin Nutr. 2002; 76(3): 
560–568, indexed in Pubmed:12198000.
36. Kumar V, Bhat ZA, Kumar D, et al. Gastroprotective effect 
of leaf extracts of Basella alba var. alba against experimen-
tal gastric ulcers in rats. Rev Bras Farmacogn. 2012; 22(3): 
657–662, doi: 10.1590/s0102-695x2012005000032.
37. Lakhanpal P, Rai DK. Quercetin: A Versatile Flavonoid. Int 
J Med Update. 2007; 2(2), doi: 10.4314/ijmu.v2i2.39851.
38. Lima CF, Fernandes-Ferreira M, Pereira-Wilson C. Phenolic 
compounds protect HepG2 cells from oxidative damage: 
relevance of glutathione levels. Life Sci. 2006; 79(21): 
2056–2068, doi:  10.1016/j.lfs.2006.06.042, indexed in 
Pubmed: 16857214.
39. Liu JL, Du J, Fan LL, et al. Effects of quercetin on hyper-
proliferation of gastric mucosal cells in rats treated with 
chronic oral ethanol through the reactive oxygen species-
nitric oxide pathway. World J Gastroenterol. 2008; 14(20): 
3242–3248, indexed in Pubmed: 18506933.
40. Malfertheiner P, Chan F, McColl K. Peptic ulcer disease. 
The Lancet. 2009; 374(9699): 1449–1461, doi: 10.1016/
s0140-6736(09)60938-7.
41. Mamani-Matsuda M, Kauss T, Al-Kharrat A, et al. Thera-
peutic and preventive properties of quercetin in experi-
mental arthritis correlate with decreased macrophage 
inflammatory mediators. Biochem Pharmacol. 2006; 
72(10): 1304–1310, doi:  10.1016/j.bcp.2006.08.001, 
indexed in Pubmed:16959220.
42. Milosavljevic T, Kostić-Milosavljević M, Jovanović I, et 
al. Complications of peptic ulcer disease. Dig Dis. 2011; 
29(5): 491–493, doi:10.1159/000331517, indexed in 
Pubmed: 22095016.
43. Mira L, Fernandez MT, Santos M, et al. Interactions of 
flavonoids with iron and copper ions: a mechanism for 
their antioxidant activity. Free Radic Res. 2002; 36(11): 
1199–1208, indexed in Pubmed: 12592672.
44. Miyamoto M, Haruma K. [Gastric ulcer and duodenal 
ulcer]. Nihon Rinsho. 2013; 71(8): 1418–1423, indexed 
in Pubmed: 23967673.
45. Moghaddam G, Sharifzadeh M, Hassanzadeh G, et al. 
Anti-Ulcerative Potential of Punica granatum L (Lythraceae) 
Hydroalcohol Fruit Peel Extract. Trop J Pharm Res. 2014; 
13(7): 1093, doi: 10.4314/tjpr.v13i7.12.
46. Myhrstad MCW, Carlsen H, Nordström O, et al. Flavonoids 
increase the intracellular glutathione level by transactiva-
tion of the gamma-glutamylcysteine synthetase catalyti-
cal subunit promoter. Free Radic Biol Med. 2002; 32(5): 
386–393, indexed in Pubmed: 11864778.
47. Naesdal J, Brown K. NSAID-associated adverse effects 
and acid control aids to prevent them: a review of cur-
rent treatment options. Drug Saf. 2006; 29(2): 119–132, 
indexed in Pubmed: 16454539.
48. Pawlikowska-Pawlega B, Gruszecki WI, Misiak LE, et al. 
The study of the quercetin action on human erythrocyte 
membranes. Biochem Pharmacol. 2003; 66(4): 605–612, 
indexed in Pubmed: 12906925.
49. Perez-Vizcaino F, Duarte J, Jimenez R, et al. Antihyperten-
sive effects of the flavonoid quercetin. Pharmacol Rep. 
2009; 61(1): 67–75, indexed in Pubmed: 19307694.
50. Polat B, Albayrak Y, Suleyman B, et al. Antiulcerative effect 
of dexmedetomidine on indomethacin-induced gastric ul-
cer in rats. Pharmacol Rep. 2011; 63(2): 518–526, indexed 
in Pubmed: 21602607.
261
A.G.R. Alkushi, N.A.M. Elsawy, Effect of quercetin’s anti-ulcer activity
51. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am 
Fam Physician. 2007; 76(7): 1005–1012, indexed in Pub-
med: 17956071.
52. Repetto MG, Llesuy SF. Antioxidant properties of natural 
compounds used in popular medicine for gastric ulcers. 
Braz J Med Biol Res. 2002; 35(5): 523–534, indexed in 
Pubmed: 12011936.
53. Robaszkiewicz A, Balcerczyk A, Bartosz G. Antioxidative 
and prooxidative effects of quercetin on A549 cells. 
Cell Biol Int. 2007; 31(10): 1245–1250, doi:  10.1016/j.
cellbi.2007.04.009, indexed in Pubmed: 17583542.
54. Russo M, Spagnuolo C, Tedesco I, et al. The flavonoid querce-
tin in disease prevention and therapy: facts and fancies. 
Biochem Pharmacol. 2012; 83(1): 6–15, doi: 10.1016/j.
bcp.2011.08.010, indexed in Pubmed: 21856292.
55. Sairam K, Rao CV, Goel RK. Effect of Convolvulus pluricaulis 
Chois on gastric ulceration and secretion in rats. Indian J Exp 
Biol. 2001; 39(4): 350–354, indexed in Pubmed: 11491580.
56. Sandhar HK, Kumar B, Prasher S, et al. Review of Phyto-
chemistry and Pharmacology of Flavonoids. Int Pharma-
ceutica Sciencia. 2011; 1: 25–41.
57. Seckin Y, Harputluoglu MMM, Batcioglu K, et al. Gastric 
tissue oxidative changes in portal hypertension and cir-
rhosis. Dig Dis Sci. 2007; 52(5): 1154–1158, doi: 10.1007/
s10620-006-9139-8, indexed in Pubmed: 17345161.
58. Sener G, Paskaloglu K, Ayanoglu-dülger G. Protective ef-
fect of increasing doses of famotidine, omeprazole, lan-
soprazole, and melatonin against ethanol-induced gastric 
damage in rats. Indian J Pharmacol. 2004; 36: 171–174.
59. Sumbul S, Ahmad MA, Mohd A, et al. Role of phenolic 
compounds in peptic ulcer: An overview. J Pharm Bioallied 
Sci. 2011; 3(3): 361–367, doi:10.4103/0975-7406.84437, 
indexed in Pubmed: 21966156.
60. Surapaneni SR, Reddy AB. The Perforation-Operation 
Time Interval; An Important Mortality Indicator in Peptic 
Ulcer Perforation. J Clin Diagn Res. 2013; 7(5): 880–882, 
doi:  10.7860/JCDR/2013/4925.2965, indexed in Pub-
med: 23814733.
61. Tang RS, Chan FKL. Therapeutic management of recurrent 
peptic ulcer disease. Drugs. 2012; 72(12): 1605–1616, 
doi:  10.2165/11634850-000000000-00000, indexed in 
Pubmed: 22867043.
62. Terao J. Dietary Flavonoids as Antioxidants. In: Yoshikawa T 
(ed.). Food Factors for Health Promotion. Forum Nutr. 
Karger, Basel 2009: pp. 87–94.
63. Thorsen K, Søreide JA, Søreide K. Epidemiology of per-
forated peptic ulcer: Age- and gender-adjusted analysis 
of incidence and mortality. World J Gastroenterol. 2013; 
19(3): 347, doi: 10.3748/wjg.v19.i3.347.
64. Toki M, Aoki K, Katsumi N, et al. [NSAID and its effect on 
prostaglandin]. Nihon Rinsho. 2007; 65(10): 1807–1811, 
indexed in Pubmed: 17926528.
65. Villegas I, La Casa C, de la Lastra CA, et al. Mucosal 
damage induced by preferential COX-1 and COX-2 
inhibitors: role of prostaglandins and inflammatory 
response. Life Sci. 2004; 74(7): 873–884, indexed in Pub-
med: 14659976.
66. Villegas I, Martín MJ, La Casa C, et al. Effects of oxicam 
inhibitors of cyclooxygenase on oxidative stress genera-
tion in rat gastric mucosa. A comparative study. Free 
Radic Res. 2002; 36(7): 769–777, indexed in Pubmed:   
12180128.
67. Webster-Gandy J, Madden A, Holdsworth M. Oxford hand-
book of nutrition and dietetics. 2nd ed. Oxford University 
Press, Oxford 2012.
68. Wiczkowski W, Nèmeth K, Buciński A, et al. Bioavailability 
of Quercetin from Flesh Scales and Dry Skin of Onion in 
Rats. Pol J Food Nutr Sci. 2003; 12: 95–99.
69. Wu LX, Guo CX, Chen WQ, et al. Inhibition of the organic 
anion-transporting polypeptide 1B1 by quercetin: an in 
vitro and in vivo assessment. Br J Clin Pharmacol. 2012; 
73(5): 750–757, doi: 10.1111/j.1365-2125.2011.04150.x, 
indexed in Pubmed: 22114872.
70. Yamazaki Y, Ueda T, Kohli Y, et al. Importance of acidic 
mucin secretions by foveolar and mucous neck cells of 
rat fundic mucosa as the defence mechanisms against 
HCl as revealed by fasting. Eur J Histochem. 1992; 36(2): 
161–176, indexed in Pubmed: 1380850.
71. Yang JH, Hsia TC, Kuo HM, et al. Inhibition of lung cancer 
cell growth by quercetin glucuronides via G2/M arrest 
and induction of apoptosis. Drug Metab Dispos. 2006; 
34(2): 296–304, doi: 10.1124/dmd.105.005280, indexed 
in Pubmed: 16280456.
72. Yao LH, Jiang YM, Shi J, et al. Flavonoids in food and 
their health benefits. Plant Foods Hum Nutr. 2004; 59(3): 
113–122, indexed in Pubmed: 15678717.
73. Ye B, Zhou PY, Jia M, et al. Absence of NF-kB subunit p50 
ameliorates cold immobilization stress-induced gastric 
ulcers. Biochem Biophys Res Commun. 2013; 434(3): 
547–551, doi:  10.1016/j.bbrc.2013.03.112, indexed in 
Pubmed: 23583384.
74. Zahorodnyĭ MI. [Effect of quercetin on sodium diclofenac-
induced ulceration]. Lik Sprava. 2003(1): 96–99, indexed 
in Pubmed: 12712624.
